Download PDF
Thromb Haemost 1989; 61(01): 093-096
DOI: 10.1055/s-0038-1646533
Original Article
Schattauer GmbH Stuttgart

Absence of Potentiation with Murine Antiplatelet GPIIb/IIIa Antibody of Thrombolysis with Recombinant Tissue-Type Plasminogen Activator (rt-PA) in a Canine Venous Thrombosis Model

D Spriggs
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
H K Gold
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
Y Hashimoto
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
E Van Houtte
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
J Vermylen
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
,
D Collen
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium and the Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
› Author Affiliations
Further Information

Publication History

Received 14 June 1988

Accepted after revision 21 September 1988

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

F(ab’)2 fragments of a murine monoclonal anti-platelet GPIIb/ IIIa antibody (7E3) are a potent platelet aggregation inhibitor, which in a canine coronary artery thrombosis model accelerate lysis with recombinant tissue-type plasminogen activator (rt-PA) and prevent reocclusion (7).

In the present study, we have investigated the potential value of platelet aggregation inhibition as adjunctive therapy to lysis of venous thrombi, by measuring the thrombolytic potency of 7E3- F(ab’)2 and rt-PA used alone or in combination, in dogs with a 125I-fibrin labeled femoral vein thrombus. The dose-response of thrombolysis with rt-PA infused over 4 hours was linear: doses of 0.075 mg/kg, 0.15 mg/kg and 0.3 mg/kg produced 37 ± 3, 57 ± 11 and 83 ± 4% lysis respectively, against a background value of 20 ± 2%. With F(ab’)2 fragments of 7E3 given as a bolus of 1.2 mg/ kg, which saturated 70% of the platelet GPIIb/IIIa receptors and prolonged the bleeding to more than 30 min, lysis was not significantly increased over background. Combination of 0.3 or 0.6 mg/kg of 7E3-F(ab’)2 with either 0.03 or 0.06 mg/kg of rt-PA did not produce more lysis than obtained with a comparable dose of rt-PA alone. No significant changes in plasma fibrinogen or α2- antiplasmin were observed with either agent alone or with the combination. It is concluded that extensive inhibition of platelet aggregation does not potentiate the thrombolytic effect of rt-PA in this venous thrombosis model.

Key words

Recombinant tissue-type plasminogen activator (rt-PA) - Platelet inhibition - Thrombolysis
 

  • References

  • 1 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda T, Bulkley BH, Robison AK, Hutter AM, Bell WR, Spadaro JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant tissue-type plasminogen activator: a prospective randomized placebo- controlled trial. Circulation 1984; 70: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 2 TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 1985; 312: 932-936
    PubMed
  • 3 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomised trial of intravenous recombinant tissue- type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842-847
    PubMedGoogle Scholar
  • 4 Joist JH. Platelets and fibrinolysis. Thromb Haemostas 1971; 38: 955-962
    PubMedGoogle Scholar
  • 5 Plow EF, Collen D. The presence and release of α2-antiplasmin from human platelets. Blood 1981; 58: 1069-1074
    PubMedGoogle Scholar
  • 6 Kruithof EK O, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemostas 1986; 55: 201-205
    PubMedGoogle Scholar
  • 7 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988; 77: 670-677
    PubMedGoogle Scholar
  • 8 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest 1983; 12: 325-338
    PubMedGoogle Scholar
  • 9 Coller BS, Folts JD, Scudder LE, Smith SR. Anti-thrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-786
    PubMedGoogle Scholar
  • 10 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415-428
    PubMedGoogle Scholar
  • 11 Fraker PJ, Speck JC. Protein and membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylgly- coluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 12 Fenton JW, Fasio MJ, Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human thrombin. Production, evaluation and properties of α-thrombins J Biol Chem 1977; 252: 3587-3598
    PubMedGoogle Scholar
  • 13 Marchalonis JJ. An enzymatic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305
    CrossrefPubMedGoogle Scholar
  • 14 Smith RA G, Dupe RJ, English PD, Green J. Fibrinolysis with acylenzymes: a new approach to thrombolytic therapy. Nature (London) 1981; 290: 505-508
    CrossrefPubMedGoogle Scholar
  • 15 Korninger C, Matsuo R, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573-578
    CrossrefPubMedGoogle Scholar
  • 16 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of thrombus and route of administration J Clin Invest 1983; 71: 368-376
    CrossrefPubMedGoogle Scholar
  • 17 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 18 Berenbaum MC. The expected effect of a combination of agents: the general solution. J Theoret Biol 1985; 114: 413-431
    CrossrefPubMedGoogle Scholar
  • 19 Collen D. Synergism of thrombolytic agents. Investigational procedures and clinical potential Circulation 1988; 77: 731-735
    CrossrefPubMedGoogle Scholar
  • 20 Collen D, Stassen JM, Stump DC, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation 1986; 14: 838-842
    PubMedGoogle Scholar
  • 21 Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. J Clin Invest 1986; 78: 1072-1082
    CrossrefPubMedGoogle Scholar
  • 22 Deykin D. Thrombogenesis. N Engl J Med 1967; 296: 622-626
    PubMedGoogle Scholar
  • 23 Harker LA, Ross R. Pathogenesis of arterial vascular disease. Sem Thromb Haemostas 1979; 5: 274-292
    PubMedGoogle Scholar
  • 24 Turitto VT, Baumgartner HR. Platelet surface interactions. In: Haemostasis and Thrombosis. Coleman RW, Hirsh J, Marder VJ, Salzman EW. (eds) J. B. Lippincott; Philadelphia: 1987. pp 555-571
    Google Scholar
  • 25 Sakariassen KS, Nievelstein PF E M, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-691
    CrossrefPubMedGoogle Scholar
  • 26 Weiss HJ, Turitto CR, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb/IIIa and storage organelles. Blood 1986; 67: 322-330
    PubMedGoogle Scholar
  • 27 George JN, Nurden AT, Philips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984; 311: 1084-1098
    CrossrefPubMedGoogle Scholar
  • 28 Mann KG, Tracy PB, Krishnaswamy S, Jenny RJ, Odegaard BH, Nesheim ME. Platelets and coagulation. Thrombosis and Haemostasis 1987. In: Verstraete M, Vermylen J, Lijnen R, Amout J. (eds) Leuven University Press: Leuven; 1987. pp 505-23
    Google Scholar